CARDIFF ONCOLOGY, INC. Cash and Restricted Cash
CARDIFF ONCOLOGY, INC. (CRDF) had Cash and Restricted Cash of $9.20 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.20M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.54M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.47M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.13M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $9.20M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $8.54M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $17.47M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $10.13M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $10.78M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $24.09M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $51.47M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $13.04M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $25.50M 10-Q · filed 2025-07-29 | |
| 2024-03-31 | $18.66M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $21.66M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $15.23M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $19.37M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $15.02M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $16.35M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $18.72M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $20.96M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $20.05M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $11.94M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $13.16M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $10.58M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $14.66M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $130.98M 10-K · filed 2023-03-02 | $130.98M 10-K · filed 2021-02-25 |
| 2020-09-30 | $36.41M 10-Q · filed 2021-11-04 | $36.41M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $27.75M 10-Q · filed 2021-08-05 | $27.75M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $9.28M 10-Q · filed 2021-05-06 | $9.28M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $10.20M 10-K · filed 2022-02-24 | $10.20M 10-K · filed 2020-02-27 |
| 2019-09-30 | $9.03M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $10.79M 10-Q · filed 2020-08-11 | |
| 2019-03-31 | $11.33M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $11.45M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $15.07M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $8.23M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |